Delivering More
PSMA PET Options for Patients and Practices

Telix puts patients first by making accurate and reliable tracers to enable clinical decision-making. With technologies to meet the needs of different institutions and ensure broad product availability, the TelixPSMA PET franchise has patients and practices covered.
Sign up for more information.
"Telix is revolutionizing cancer care as the vanguard of next-gen molecular imaging — a cornerstone to precision medicine — thus setting a new standard in the diagnosis of prostate cancer"
Paul M. Yonover, MD, FACS
Urology
"PSMA imaging from Telix Pharmaceuticals provides a clearer vision in the fight against prostate cancer. This allows for more accurate staging and effective treatment strategies to lead to optimal patient outcomes"
Ramji Rajendran, MD
Radiation Oncology
"PSMA PET imaging made possible by Telix has been an immensely powerful diagnostic tool across the entire life-cycle of prostate cancer, making better diagnosis and treatment a reality"
Brad Fehrenbach, MD
Nuclear Medicine
"PSMA PET CT is the standard of care and my first choice for precise staging and treatment planning for my patients with prostate cancer"
Paul Dato, MD
Urology
"68Ga-PSMA-11 has revolutionized prostate cancer staging and surveillance at our cancer center. It gives us great confidence in our treatment recommendations knowing that we have a sensitive and accurate scan with minimal indeterminate findings"
Amir Lavaf, MD
Radiation Oncology

“Telix is revolutionizing cancer care as the vanguard of next-gen molecular imaging — a cornerstone to precision medicine — thus setting a new standard in the diagnosis of prostate cancer”

Paul M. Yonover, MD, FACS

Urology

“PSMA imaging from Telix Pharmaceuticals provides a clearer vision in the fight against prostate cancer. This allows for more accurate staging and effective treatment strategies to lead to optimal patient outcomes”

Ramji Rajendran, MD

Radiation Oncology

“PSMA PET imaging made possible by Telix has been an immensely powerful diagnostic tool across the entire life-cycle of prostate cancer, making better diagnosis and treatment a reality”

Brad Fehrenbach, MD

Nuclear Medicine

“PSMA PET CT is the standard of care and my first choice for precise staging and treatment planning for my patients with prostate cancer”

Paul Dato, MD

Urology

“68Ga-PSMA-11 has revolutionized prostate cancer staging and surveillance at our cancer center. It gives us great confidence in our treatment recommendations knowing that we have a sensitive and accurate scan with minimal indeterminate findings”

Amir Lavaf, MD

Radiation Oncology

Explore our 68Ga-PSMA-11 imaging solutions

Visit the Gozellix healthcare professional site to see how we're shattering limitations in PSMA.
Visit the Illuccix healthcare professional site
68Ga-PSMA-11 is a radiotracer that binds with high affinity to PSMA and in doing so can reveal prostate cancer cells in the body. Gallium 68 (Ga 68) gozetotide binds to PSMA.1 It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Ga 68 is a β+ emitting radionuclide that allows PET.2
References: 1. Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The evolving role of prostate-specific membrane antigen-based diagnostics and therapeutics in prostate cancer. Am Soc Clin Oncol Educ Book. 2019;39:321-330. 2. Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) prescribing information.